EyePoint’s DURAVYU Misses Primary Endpoint in Second Wet AMD Trial
LUCIA showed lower treatment burden and favorable safety, but DURAVYU did not meet the trial’s primary measure of visual acuity.
Makkler Newsroom · Oct 19, 02:22 PM · 1 min read
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO